Angiotensin II increases mRNA levels of all TGF-β isoforms in quiescent and activated rat hepatic stellate cells

Cell Biology International

Volumn 34, Issue 10, 2010, Pages 969-978

  Moreno Alvarez, Paola ^a   Sosa Garrocho, Marcela ^a   Briones Orta, Marco A ^a   González Espinosa, Claudia ^b   Medina Tamayo, Jaciel ^b   Molina Jijón, Eduardo ^a   Pedraza Chaverri, José ^a   Macías Silva, Marina ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Angiotensin II; Hepatic stellate cell; Liver; MAPK; Nox; TGF

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; STELLATE CELL; TRANSACTIVATION; UPREGULATION;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELLS; LUCIFERASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NADPH OXIDASE; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

RATTUS;

EID: 77957348899     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20090074     Document Type: Article

References (67)

1. Andresen BT, Linnoila JJ, Jackson EK, Romero GG. Role of EGFR transactivation in angiotensin II signaling to extracellular regulated kinase in preglomerular smooth muscle cells. Hypertension 2003;41:781-6.
2. Adachi T, Togashi H, Suzuki A, Kasai S, Ito J, Sugahara K et al. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 2005;41:1272-81.
3. Baer HU, Friess H, Abou-Shady M, Berberat P, Zimmermann A, Gold LI et al. Transforming growth factor betas and their receptors in human liver cirrhosis. Eur J Gastroenterol Hepatol 1998;10:1031-9.
4. Ballardini G, Fallani M, Biagini G, Bianchi FB, Pisi E. Desmin and actin in the identification of Ito cells and in monitoring their evolution to myofibroblasts in experimental liver fibrosis. Virchows Arch B Cell Pathol Incl Mol Pathol 1988;56:45-9.
5. Bascom CC, Wolfshohl JR, Coffey RJ, Madisen L, Webb NR, Purchio AR et al. Complex regulation of transforming growth factor β1, β2, and β3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors β1 and β2. Mol Cell Biol 1989;9: 5508-15.
6. Bataller R, Gines P, Nicolas JM, Görbig MN, Garcia-Ramallo E, Gasull X et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-56.
7. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 2003a;285:G642-51.
8. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003b;112:1383-94.
9. Bedard K, Krause KH. The NOX Family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
10. Bindokas V, Jordan J, Lee C, Millar R. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci 1996;16:1324-36.
11. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F et al. Hepatic hemodynamics and the renin angiotensin system in cirrhosis. Gastroenterology 1980;78:92-9.
12. Choi SS, Sicklick JK, Yang L, Huang J, Qi Y, Chen W et al. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. Hepatology 2006;44:1267-77.
13. Czaja M. Another way for NADPH oxidase to send a signal for liver injury. Gastroenterology 2005;129:2110-13.
14. De Bleser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factorbeta gene expression in normal and fibrotic rat liver. J Hepatol 1997;26:886-93.
15. De Gasparo M, Catt K, Inagami T, Wright JW, Unger T. International Union of Pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
16. De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: defensive, offensive or fibrogenic? Gastroenterology 2006;131:272-5.
17. De Minicis S, Brenner DA. Nox in liver fibrosis. Arch Biochem Biophys 2007;462:266-72.
18. Dinh D, Frauman A, Jonhston C, Fabiani M. Angiotensin receptors: distribution, signaling and function. Clin Sci 2001;100:481-92.
19. Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, Motley ED. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology 2000;141:3120-6.
20. Friedman SL, Roll FJ. Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Anal Biochem 1987;161:207-18.
21. Friedman S. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50.
22. Friedman S. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-72.
23. Fukumura Y, Kumasaka T, Mitani K, Karita K, Suda K. Expression of transforming growth factor beta1, beta2, and beta3 in chronic, cancer-associated, obstructive pancreatitis. Arch Pathol Lab Med 2006;130:356-61.
24. García-Sáinz JA, Macías-Silva M. Angiotensin II stimulates phosphoinositide turnover and phosphorylase through AII-1 receptors in isolated rat hepatocytes. Biochem Biophys Res Commun 1990;172:780-5.
25. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009;302:148-58.
26. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001;21:311-35.
27. González-Espinosa C, Odom S, Olivera A, Hobson JP, Martinez ME, Oliveira-Dos-Santos A et al. Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. J Exp Med 2003;197:1453-65.
28. Gorin Y, Ricono JM, Wagner B, Kim NH, Bhandari B, Choudhury GG et al. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J 2004;381:231-9.
29. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
30. Hamaguchi A, Kim S, Izumi Y, Zhan Y, Yamanaka S, Iwao H. Contribution of extracellular signal-regulated kinase to angiotensin II-induced transforming growth factor-β1 expression in vascular smooth muscle cells. Hypertension 1999;34:126-31.
31. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol 1999;30:77-87.
32. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001;170:647-51.
33. 4. Biochem Biophys Res Commun 2003;308:177-83.
34. Kim SJ, Denhez F, Kim KY, Holt JT, Sporn MB, Roberts AB. Activation of the second promoter of the transforming growth factor-β1 gene by transforming growth factor-β1 and phorbol ester occurs through the same target sequences. J Biol Chem 1989;264:19373-8.
35. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB et al. Autoinduction of transforming growth factor 1 is mediated by the AP-1 complex. Mol Cel Biol 1990;10:1492-7.
36. Lafyatis R, Lechleider R, Kim SJ, Jakowlew S, Roberts AB, Sporn MB. Structural and functional characterization of the transforming growth factor beta 3 promoter. A cAMP-responsive element regulates basal and induced transcription. J Biol Chem 1990;265:19128-36.
37. Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J 2004;18:816-27.
38. Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 2000;58:2367-76.
39. Lu L, Saulis AS, Liu WR, Roy NK, Chao JD, Ledbetter S et al. The temporal effects of anti-TGF-β1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg 2005;201:391-7.
40. Lu D, Giguere, V. Requirement of ras-dependent pathways for activation of the transforming growth factor β3 promoter by estradiol. Endocrinology 2001;142:751-9.
41. Macías-Silva M, Abdollah S, Pirone R, Hoodless PA, Attisano L, Wrana JL. MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996;87:1215-24.
42. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002;282:C172-82.
43. Mehta PK, Griendling KK. Angiotensin II cell signalling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97.
44. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001;38:635-8.
45. Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis 2008;12:825-52.
46. O'Kane S, Ferguson MWJ. Transforming growth factor βs and wound healing. Int J Biochem Cell Biol 1997;1:63-78.
47. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernández JR. Angiotensin II and the development of insulin resistance: Implications for diabetes. Mol Cell Endocrinol 2009;302:128-39.
48. Orozco-Ibarra M, Estrada-Sánchez AM, Massieu L, Pedraza-Chaverri J. Heme oxygenase-1 induction prevents neuronal damage triggered during mitochondrial inhibition: role of CO and bilirubin. Int J Biochem Cell Biol 2009;41:1304-14.
49. O'Reilly MA, Geiser AG, Kim SJ, Bruggeman LA, Luu AX, Roberts AB et al. Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-beta 2 promoter. J Biol Chem 1992;267:19938-43.
50. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416.
51. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type b transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999;96:2345-9.
52. Roberts A. Molecular and cell biology of TGF-β. Miner Electrolyte Metab 1998;24:111-9.
53. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press;1989
54. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003;10 Suppl 1:S59-67.
55. Shah BH, Yesilkaya A, Olivares-Reyes JA, Chen HD, Hunyady L, Catt KJ. Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. Mol Endocrinol 2004;18:2035-48.
56. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002;35:1001-15.
57. Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 2006;41:996-1004.
58. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci 2007;113:109-18.
59. Wei H, Lu H, Li D, Zhan Y, Wang Z, Huang X. The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4. Chin Med J (Engl) 2001;114:583-7.
60. Weigert C, Brodbeck K, Klopfer K, Häring HU, Schleicher ED. Angiotensin II induces TGF-β1 promoter activation: similarity to hyperglycemia. Diabetologia 2002;45:890-8.
61. Wickert L, Steinkrüger S, Abiaka M, Bolkenius U, Purps O, Schnabel C et al. Quantitative monitoring of the mRNA expression pattern of the TGF-b-isoforms (b1, b2, b3) during transdifferentiation of hepatic stllate cells using a newly developed real-time SYBR Green PCR. Biochem Biophys Res Commun 2002;295:330-5.
62. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
63. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011-22.
64. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T et al. Angiotensin II type I receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-50.
65. Yu L, Border WA, Huang Y, Noble NA. TGF-β isoforms in renal fibrogenesis. Kidney Int 2003;64:844-56.
66. Zhang Y, Yang X, Wu P, Xu L, Liao G, Yang G. Expression of angiotensin II type 1 receptor in rat hepatic stellate cells and its effects on cell growth and collagen production. Horm Res 2003;60:105-10.
67. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I et al. Protein kinase C, but not tyrosine kinases or ras, plays a critical role in angiotensin II-induced activation of raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem 1996;271:33592-7.